Rainier Therapeutics Email Format

Pharmaceutical ManufacturingCalifornia, United States11-50 Employees

Rainier Therapeutics is a privately held biotechnology company developing biologic therapies for medical conditions with limited treatment options. Its lead candidate, B-701, is a human monoclonal antibody designed to inhibit FGFR3 signaling by blocking its activity. The program is described as the most advanced FGFR3-specific antagonist currently in development. 

Headquartered in San Leandro, California, the firm operates within the pharmaceutical manufacturing sector and maintains a relatively small team. Its work centers on translating biologic science into therapies aimed at unmet clinical needs.

Sign up for free to view info

Company overview Employee directory